Indo-Bangla Pharmaceuticals Limited (DSE:IBP)

DSE:IBP Cash Flow Statement

Financials in millions BDT. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jul 1, 2022	Jul 1, 2021
Net Income	-36.83	-40.98	8.41	25.17	134.73
Depreciation & Amortization	28.46	28.54	38.36	39.13	35.9
Loss (Gain) From Sale of Assets	6.06	-	-0.7	-	0.77
Other Operating Activities	-22.93	14.32	21.4	-1.54	7.69
Change in Accounts Receivable	6.02	21.39	-4.72	26.82	-19.67
Change in Inventory	57.89	17.02	2.47	21.01	-11.8
Change in Accounts Payable	17.62	0.02	-0.09	0.31	0.25
Change in Other Net Operating Assets	2.16	-6.55	7.82	-23.61	3.17
Operating Cash Flow	58.45	33.77	72.95	87.28	151.02
Operating Cash Flow Growth	73.09%	-53.71%	-16.42%	-42.20%	-13.96%
Capital Expenditures	-0.56	-10.13	-30.03	-39.68	-200.41
Sale (Purchase) of Real Estate	-	-	-13.44	-14.5	-
Investing Cash Flow	-0.56	-10.13	-43.47	-54.18	-200.41
Short-Term Debt Issued	-	-	-	-	84.94
Total Debt Issued	-	-	-	-	84.94
Short-Term Debt Repaid	-4.2	-19.41	-31.75	-9.59	-
Total Debt Repaid	-4.2	-19.41	-31.75	-9.59	-
Net Debt Issued (Repaid)	-4.2	-19.41	-31.75	-9.59	84.94
Common Dividends Paid	-1.16	-0.29	-10.4	-24.79	-26.91
Other Financing Activities	-58.58	-4.85	-4.72	-5.63	-
Financing Cash Flow	-63.94	-24.55	-46.87	-40	58.03
Miscellaneous Cash Flow Adjustments	-	-0	-	0	13.11
Net Cash Flow	-6.05	-0.91	-17.39	-6.9	21.75
Free Cash Flow	57.89	23.64	42.92	47.6	-49.39
Free Cash Flow Growth	144.90%	-44.92%	-9.84%	-	-
Free Cash Flow Margin	31.43%	13.38%	11.46%	9.82%	-6.31%
Free Cash Flow Per Share	0.50	0.20	0.37	0.41	-0.43
Cash Interest Paid	1.87	4.85	4.72	5.63	-
Cash Income Tax Paid	-	3.6	-	13.72	16.35
Levered Free Cash Flow	97.36	29.92	15.65	75.07	-74.57
Unlevered Free Cash Flow	98.53	32.67	18.92	78.12	-72.19
Change in Working Capital	83.7	31.89	5.48	24.52	-28.06

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.